With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...
Kinder Morgan, Inc. today announced its preliminary 2025 financial projections. "We expect 4% growth from 2024 in Adjusted EBITDA and 8% growth in Adjusted EPS due to growth projects in all our ...
Vail Resorts, Inc. today reported results for the first quarter of fiscal 2025 ended October 31, 2024, provided season pass sales results for the 2024/2025 season, updated fiscal 2025 net income ...